NeurAxon, Inc. to Present at Upcoming Investor and Business Development Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will be presenting at the following conferences:

“US Healthcare Reform: The International Impact on Innovation and the Business of Biotech”

• The BIO Investor Forum on Wednesday, October 28th at 2:30 pm Pacific Time in the Sea Cliff room at the Palace Hotel in San Francisco.
• BIO-Europe on Tuesday, November 3rd at 4:00 pm Central European Time in room Schubert 2 at the Messe Wien Exhibition & Congress Center in Vienna, Austria.

These presentations will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine.

• Additionally, NeurAxon is pleased to announce that John S. Andrews, Ph.D., the Company’s President and Head of R&D, has been invited to participate in the Spotlight Track session “US Healthcare Reform: The International Impact on Innovation and the Business of Biotech” at BIO-Europe in Vienna, Austria on Monday, November 2nd at 4:00 pm. The 60-minute panel discussion will cover how U.S. health care reform may affect innovation and specifically business development opportunities.

About NeurAxon, Inc.

NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.